Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (FLGT) delivers innovative genetic testing and diagnostic solutions through its dual focus on clinical laboratory services and oncology therapeutic development. This news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, scientific advancements, and strategic initiatives.
Access authoritative reporting on earnings announcements, regulatory milestones, and partnership developments alongside analysis of FLGT’s expanding test menu and cancer research programs. Our curated news collection enables efficient tracking of operational updates across both laboratory services and drug development segments.
Key content includes coverage of diagnostic technology innovations, clinical trial progress, and healthcare collaborations that shape FLGT’s position in precision medicine. All materials are vetted for relevance to investment analysis and clinical practice trends.
Bookmark this page for streamlined access to Fulgent Genetics’ latest corporate developments, with new content added as official announcements are released through regulatory channels and company communications.
Fulgent Genetics (NASDAQ: FLGT), a technology-based company operating in laboratory services and therapeutic development, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025, before market opening.
The company will host an investment community conference call at 8:30 AM ET (5:30 AM PT) on the same day. Management will present the results and conduct a Q&A session. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Fulgent Genetics (NASDAQ: FLGT) has reported its financial results for Q4 and full year 2024. The company achieved total revenue of $283.5 million for the full year, with core revenue growing 7% year-over-year to $281.2 million.
Key financial highlights include:
- Q4 total revenue of $76.2 million with core revenue up 14% year-over-year to $76.0 million
- Full year GAAP loss of $42.7 million, or ($1.41) per share
- Non-GAAP income of $15.0 million, or $0.49 per share
- Strong cash position of $828.6 million ($26.87 per share)
For 2025, Fulgent projects core revenue of approximately $310 million, with an expected GAAP loss of ($1.95) per share and non-GAAP loss of ($0.65) per share. The company anticipates ending 2025 with approximately $780 million in cash and investments.
Fulgent Genetics (NASDAQ: FLGT) has announced it will release its fourth quarter and full year 2024 financial results before market opens on Friday, February 28, 2025. The company will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day, where management will discuss results and answer questions. The call will be accessible through a live audio webcast on the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Foundation Medicine announced plans to launch two new germline tests in the United States through a partnership with Fulgent Genetics (NASDAQ: FLGT). The tests, FoundationOne®Germline and FoundationOne®Germline More, will be available from February 28, 2025, and can be added to any Foundation Medicine comprehensive genomic profiling test.
FoundationOne®Germline analyzes 50 genes associated with hereditary cancers, while FoundationOne®Germline More is an expanded panel analyzing 154 genes. Both tests use Fulgent's proprietary technology platform to analyze single nucleotide and copy number variations. When combined with Foundation Medicine's existing tests, they help healthcare providers build comprehensive molecular profiles for cancer patients, explaining cancer development and potential future cancer risks.
Fulgent Genetics (NASDAQ: FLGT) reported Q3 2024 financial results with total revenue of $71.7 million, representing a 9% year-over-year growth in core revenue. The company posted a GAAP loss of $14.6 million (-$0.48 per share) and non-GAAP income of $9.4 million ($0.31 per share). The company maintains strong liquidity with $815.4 million in cash and investments.
Fulgent reiterates its full-year 2024 core revenue guidance of $280 million and improves its GAAP loss guidance from -$1.95 to -$1.70 per share. The company also revised its non-GAAP outlook from a loss of $0.30 per share to an income of $0.33 per share.
Fulgent Genetics (NASDAQ:FLGT) has announced its management team's upcoming participation in two major healthcare conferences. The company will present at the UBS Global Healthcare Conference on November 12th at 2:45 PM Pacific Time and the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:30 AM Eastern Time.
Live webcasts of both presentations will be available on Fulgent's Investor Relations website, with replay options accessible approximately one hour after each event concludes.
Fulgent Genetics (NASDAQ: FLGT) has secured a five-year contract worth up to $99M from the U.S. Department of Veterans Affairs to provide hereditary cancer and pharmacogenetic testing to Veterans. The company, which has been offering genetic testing services to VA members since 2017, will expand its services to include hereditary cancer tests for individuals with cancer or family history of certain cancers. The contract also covers pharmacogenetic testing, which uses genomic information to determine medication responses. Fulgent's comprehensive suite of germline tests enables custom solutions, utilizing next-generation sequencing for higher resolution and greater coverage.
Fulgent Genetics (NASDAQ: FLGT) has announced it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. The company, which operates a laboratory services business and a therapeutic development business, will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day.
Management will discuss the results and answer questions during the call. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website at http://ir.fulgentgenetics.com. An audio replay will also be available at the same location following the call.
Fulgent Genetics (NASDAQ: FLGT) reported Q2 2024 financial results with total revenue of $71.0 million. Core Revenue grew 5% year-over-year to $70.2 million. The company reported a GAAP loss of $8.7 million, or ($0.29) per share, and Non-GAAP income of $4.7 million, or $0.15 per share. Fulgent reiterated its Full Year 2024 Core Revenue Guidance of $280 million and improved its Earnings Per Share Guidance. The company maintains a strong cash position with $837.9 million in cash, cash equivalents, and investments as of June 30, 2024. Fulgent's Laboratory Services continue to show strength, particularly in Precision Diagnostics, while its Therapeutics Development segment progresses with clinical trials.
Fulgent Genetics (NASDAQ: FLGT) will announce its second quarter 2024 financial results on Friday, August 2, 2024, before the market opens.
The company will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day to discuss the results and answer questions.
The live audio webcast and replay will be accessible on Fulgent's Investor Relations website.
